Background {#Sec1}
==========

Liver tumors among children are relatively rare, accounting for approximately 1% of all childhood malignancies \[[@CR1]--[@CR4]\]. The overall age-standardized rate of incidence (world standard) of liver tumors in children was 2.3 per million person-years between 2001 and 2010 worldwide \[[@CR5]\]. Hepatoblastoma is the most common malignant liver tumor in children, with an increase in incidence of 4.3% per year, from 1992 to 2004, in children younger than 19 years \[[@CR1], [@CR4], [@CR6], [@CR7]\]. Hepatoblastoma is most frequently diagnosed in children less than 5 years of age \[[@CR3], [@CR7]--[@CR9]\]. Treatment of hepatoblastoma includes chemotherapy, surgical resection, and liver transplantation \[[@CR10]\]. Complete surgical resection is the first-line treatment for resectable hepatoblastoma at initial diagnosis, and liver transplantation is one of the main treatments for unresectable hepatoblastoma \[[@CR11]--[@CR13]\]. Survival outcomes have greatly improved over the past four decades \[[@CR10], [@CR11], [@CR14], [@CR15]\]. Although the prognostic factors and prognosis of hepatoblastoma have been reported in some population-based studies \[[@CR8], [@CR14], [@CR16], [@CR17]\], nomograms to predict long-term survival for patients with hepatoblastoma are still lacking.

Nomograms have been developed for some cancers and are accepted as reliable tools for individualized risk prediction \[[@CR18]--[@CR21]\]. Given the rarity of hepatoblastoma as well as the small sample sizes of retrospective studies \[[@CR11], [@CR15], [@CR22]--[@CR24]\], a large population-based study is needed. Therefore, we analyzed the incidence trends and clinical outcomes of hepatoblastoma in children using the data from 18 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) database, which is supported by the Surveillance Research Program (SRP) of Division of Cancer Control and Population Sciences (DCCPS) of the National Cancer Institute (NCI), and constructed a prognostic nomogram to predict long-term survival of patients with hepatoblastoma.

Methods {#Sec2}
=======

Case selection from the SEER database {#Sec3}
-------------------------------------

Data from the SEER database for year 2004--2015 were analyzed. The selection criteria were patients of 0 to 18 years old who were newly diagnosed with hepatoblastoma between January 1, 2004 and December 31, 2015. Exclusion criteria were unknown ethnicity, unknown surgical intervention, and lack of follow-up. The following variables were obtained from the SEER database for further analysis: sex, age at diagnosis, ethnicity, year of diagnosis, tumor size, tumor stage, alpha-fetoprotein (AFP) status, and surgery at the primary site.

Definition of variables {#Sec4}
-----------------------

Because the Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) staging system is not used for hepatoblastoma cases in the SEER database, the SEER summary staging guidelines \[[@CR25]\] were used to evaluate tumor stage in this analysis. The SEER variable "Summary Stage 2000 (1998+)" describes a surgical procedure that removes and/or destroys the tissue at the primary site performed as part of the initial work-up or first course of therapy. This enabled classifying cases into four categories: local, regional, distant, and unstaged. The SEER surgery codes recorded data on liver-directed surgical treatments, which were categorized as no surgery, liver resection, and liver transplantation. Sex was classified as male and female. The SEER program classified ethnicity into three categories: Caucasian ethnicity, African--American ethnicity, and other ethnicities (American Indian/Alaska Native, Asian/Pacific Islander). Age at diagnosis was classified into three groups: 0--1, 2--4, and 5--18 years old. Year of diagnosis was divided into three time periods: 2004--2007, 2008--2011, and 2012--2015. Tumor size was also classified into three categories: ≤ 5 cm, \> 5 cm, and unknown. AFP status was classified into three categories: positive, negative, and unknown (according to the SEER database). Because all patient information in the SEER database is de-identified, this study was exempted from review by the Institutional Review Board.

Statistical analysis {#Sec5}
--------------------

The age-standardized incidence of hepatoblastoma according to the 2000 US Standard Population was identified in the cancer registries of the SEER database \[[@CR26]\]. The annual percentage change (APC) of incidence was calculated using the weighted least squares method. We analyzed the incidence of hepatoblastoma stratified by sex, age at diagnosis, and ethnicity. Joinpoint regression analyses (v. 4.6.0, IMS, Calverton, MD, USA) were used to analyze incidence trends from 2000 to 2015. Overall survival (OS) was estimated using the Kaplan--Meier method, and the log-rank test was used to compare survival curves. OS was defined as the period from diagnosis to death of any cause. For individuals who were still alive at the time of the last follow-up, OS was censored at the date of last follow-up or December 31, 2015, whichever came first.

A Cox proportional hazards model was applied for multivariate survival analysis. Those variables with a *P* value less than 0.05 in the univariate analysis were entered into a Cox proportional hazards model to identify independent predictors of OS. A nomogram was constructed based on the results of the multivariate analysis. Nomogram performance was measured using the concordance index (C-index). The larger the C-index, the more accurate the prognostic prediction proved to be. The nomogram was subjected to 1000 bootstraps resamples for internal validation. Calibration of the nomogram for 5- and 10-year OS was performed by comparing predicted survival with observed survival. The data were analyzed using SPSS version 20.0 for Windows (SPSS Inc., Chicago, IL, USA) and R software version 3.5.0 (<https://www.r-project.org/>). All *P* values were two-sided, and a *P* value \< 0.05 was regarded as statistically significant.

Results {#Sec6}
=======

Patient demographics {#Sec7}
--------------------

Using the latest data released in April 2018, we identified 523 eligible individuals using the topography and morphology codes from the third edition of the International Classification of Diseases for Oncology (ICD-O-3). Of these 523 cases, we excluded 12 due to lack of data on ethnicity (*n* = 7), surgery (*n* = 2), or follow-up (*n* = 3). The remaining 511 cases were selected for this study. The median age at diagnosis was 1 year old (range 0--17 years). The majority of patients were males (62.6%), of Caucasian ethnicity (76.7%), and had a positive AFP status (82.4%). Surgery was performed on 425 (83.2%) patients. Of them, 341 (66.7%) received a liver resection, and 84 (16.4%) had liver transplantation. Baseline patient demographics and tumor characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic and clinicopathologic characteristics, and overall survival of patients with hepatoblastomaCharacteristicPatients \[cases (%)\]Deaths \[cases (%)\]Overall survival rate (%)*P* value5-year10-yearAll patients5118281.581.0Sex0.139 Male320 (62.6)58 (70.7)79.378.4 Female191 (37.4)24 (29.3)85.685.6Ethnicity0.001 Caucasian392 (76.7)55 (67.1)83.983.9 African--American44 (8.6)15 (18.3)58.458.4 Others75 (14.7)12 (14.6)82.579.0Age at diagnosis0.013 0--1323 (63.2)41 (50.0)85.885.8 2--4152 (29.7)36 (43.9)72.971.0 5--1836 (7.1)5 (6.1)79.979.9Year of diagnosis0.108 2004--2007150 (29.4)35 (42.7)76.675.8 2008--2011175 (34.2)25 (30.5)84.8NR 2012--2015186 (36.4)22 (26.8)NRNRTumor size\< 0.001 ≤ 5 cm60 (11.7)2 (2.4)96.496.4 \> 5 cm400 (78.3)62 (75.6)82.281.5 Unknown51 (10.0)18 (22.0)60.460.4Tumor stage\< 0.001 Local231 (45.2)17 (20.7)91.091.0 Regional157 (30.7)27 (32.9)80.480.4 Distant109 (21.3)34 (41.5)65.765.7 Unstaged14 (2.7)4 (4.9)77.464.5AFP status0.028 Negative10 (2.0)1 (1.2)89.489.4 Positive421 (82.4)61 (74.4)83.482.7 Unknown80 (15.7)20 (24.4)70.970.9Surgery type\< 0.001 No surgery86 (16.8)46 (56.1)43.239.4 Liver resection341 (66.7)29 (35.4)89.389.3 Liver transplantation84 (16.4)7 (8.5)90.190.1*NR* not reached, *AFP* alpha-fetoprotein

Incidence trends {#Sec8}
----------------

The incidence of hepatoblastoma increased from 1.89 per 1,000,000 in 2000 to 2.16 per 1,000,000 in 2015, with an APC of 2.2% (95% confidence interval \[CI\] 0.5% to 3.8%, *P *= 0.014). We identified a significant increase in hepatoblastoma incidence from 2000 to 2015 in the male population with an APC of 2.1% (95% CI 0.1% to 4.2%, *P* = 0.047). The rise in incidence was not significant among females (APC = 2.1%, 95% CI − 1.3% to 5.6%, *P *=0.218) (Fig. [1](#Fig1){ref-type="fig"}a). Age-adjusted incidences (95% CI) were 11.19 (9.71--12.82) per 1,000,000 in the 0- to 1-year-old age group, 5.66 (5.13--6.24) per 1,000,000 in the 2- to 4-year-old age group, and 0.18 (0.14--0.24) per 1,000,000 in the 5- to 18-year-old age group. Incidence among 2- to 4-year-old children increased significantly (APC = 3.6%, 95% CI 1.5% to 5.7%, *P* = 0.003), whereas the increase was not significant among 0- to 1-year-old children (APC = 0.4%, 95% CI − 2.2% to 3.2%, *P* = 0.803) or 5- to 18-year-old children (APC = 0.4%, 95% CI − 3.2% to 4.1%, *P* = 0.782) (Fig. [1](#Fig1){ref-type="fig"}b). The incidence among African--Americans also increased significantly (APC = 7.5%, 95% CI 2.5% to 12.8%, *P* = 0.006), which was not the case for Caucasians (APC = 1.8%, 95% CI − 0.2% to 3.8%, *P* = 0.075) and patients of other ethnicities (APC = − 0.1%, 95% CI − 4.4% to 4.4%, *P* = 0.945) (Fig. [1](#Fig1){ref-type="fig"}c).Fig. 1Hepatoblastoma incidence trends by sex (**a**), age at diagnosis (**b**), and ethnicity (**c**) among patients aged less than 18 recorded in 18 registries of the SEER database, 2004 to 2015. \*APCs significantly different than zero at the 5% level, calculated based on a two-sided *t* test. *SEER* the Surveillance, Epidemiology, and End Results database, *APC* annual percentage change

Survival {#Sec9}
--------

The median follow-up was 45 months (range 0--143 months). Overall, 82 (16.0%) patients died during follow-up. Of these, 46 (56.1%) did not undergo surgery, 29 (35.4%) had liver resection, and 7 (8.5%) had liver transplantation. The 5- and 10-year OS rates were 81.5% and 81.0%, respectively. Risk factors associated with short OS included African--American ethnicity, an age of 2--4 years, distant disease at diagnosis, large tumor size (\> 5 cm in diameter), positive AFP status, and not receiving surgery (Table [1](#Tab1){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). Type of surgery (liver resection vs. transplantation) did not have an impact on OS rate (*P* = 0.891).Fig. 2Kaplan--Meier overall survival curves of hepatoblastoma patients stratified by ethnicity (**a**), age at diagnosis (**b**), tumor stage (**c**), tumor size (**d**), AFP status (**e**), and treatment (**f**)

Regression analysis using a multivariable Cox proportional hazards model revealed that age of 2--4 years (HR = 1.66, 95% CI 1.03--2.67, *P* = 0.037) and African--American ethnicity (HR = 2.19, 95% CI 1.21--3.96, *P* = 0.010) were independent predictors of shorter OS, whereas liver resection (HR = 0.14, 95% CI 0.08--0.23, *P* \< 0.001) and liver transplantation (HR = 0.11, 95% CI 0.05--0.25, *P* \< 0.001) were independent predictors of longer OS (Fig. [3](#Fig3){ref-type="fig"}). In a multivariate survival analysis that included all variables except for surgery type, tumor stage was found to be an independent factor for OS, but AFP status was still not an independent factor of OS (Table [2](#Tab2){ref-type="table"}).Fig. 3Multivariate analysis of factors of overall survival (OS) of hepatoblastoma patients Table 2Multivariate Cox regression analysis including all variables without surgery type for overall survival of hepatoblastoma patientsCharacteristicHR95% CI*P* valueSex MaleReference Female0.720.44--1.180.195Ethnicity CaucasianReference African--American2.881.55--5.360.001 Others1.020.54--1.940.947Age at diagnosis (years) 0--1Reference 2--41.641.03--2.610.038 5--181.060.41--2.710.909Year of diagnosis 2004--2007Reference 2008--20110.680.40--1.160.155 2012--20150.840.47--1.480.540Tumor size ≤ 5 cmReference \> 5 cm3.810.92--15.720.065 Unknown6.131.39--27.090.017Tumor stage LocalReference Regional2.041.10--3.790.024 Distant3.421.87--6.26\< 0.001 Unstaged2.490.77--8.070.129AFP status NegativeReference Positive2.190.30--16.150.442 Unknown3.010.39--23.180.291*HR* hazard ratio, *CI* confidence interval, *AFP* alpha-fetoprotein

Nomogram for prediction of OS {#Sec10}
-----------------------------

We then constructed a nomogram that incorporated all significant prognostic factors identified through multivariate analysis (Fig. [4](#Fig4){ref-type="fig"}). The nomogram showed that surgery was the most significant predictor of OS, followed by ethnicity and age. The nomogram also displayed a good C-index of 0.79 (95% CI 0.74--0.84) for predicting OS. The calibration plot for the probability of 5- and 10-year OS showed an optimal agreement between actual observation and the nomogram's prediction (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4Nomogram for predicting 5- and 10-year overall survival (OS) of hepatoblastoma patients. Minimum and maximum values for OS: Caucasian ethnicity 83.9%--90.1%, African--American ethnicity 58.4%--80.2%, other ethnicities 79.0%--90.1%; 0--1 year old 85.8%--90.0%, 2--4 years old 71.0%--86.0%, 5--18 years old 79.9%--97.0%; no surgery 39.4%--54.6%, liver resection 89.3%--96.2%, liver transplantation 90.1%--97.5% Fig. 5Calibration curves for 5- (**a**) and 10-year overall survival (**b**) of hepatoblastoma patients

Discussion {#Sec11}
==========

In this population-based study, we assessed temporal trends in pediatric hepatoblastoma incidence and constructed a nomogram to provide an individualized prediction of OS. The current analysis showed a significant annual increase (2.2%) in hepatoblastoma incidence between 2000 and 2015. Although management of this disease has evolved over the past 30 years, there is no model for predicting OS of hepatoblastoma patients. The constructed nomogram was found to be accurate in prognostic prediction for hepatoblastoma patients, with a C-index of 0.79.

Owing to the rarity of hepatoblastoma, single-institution data were insufficient for assessing its incidence trends. Until now, only a few population-based studies have reported hepatoblastoma incidence trends in the past few decades. Darbari et al. \[[@CR1]\] reported the incidence of primary liver malignancies among U.S. children aged less than 20 years from 1973 to 1997, using the SEER database. They found that hepatoblastoma incidence had increased, with age-adjusted incidences of 1.09 per 1,000,000 for the whole cohort, 1.22 per 1,000,000 for males, and 0.96 per 1,000,000 for females. However, clinical outcomes and prognostic factors were not reported. In another SEER study of 606 patients diagnosed with hepatoblastoma between 1973 and 2009, Allan et al. \[[@CR8]\] found a significant increase in the overall age-adjusted incidence of hepatoblastoma with an APC of 2.18%. However, the reported incidence was not stratified by sex and age. Although outcomes and prognostic factors were reported, the study did not provide a new prognostic model. A recent population-based study analyzing the Taiwan Cancer Registry (TCR) database reported that, from 1995 to 2012, the overall incidence of hepatoblastoma in children increased by 7.4% per year and, specifically, by 6.5% among males \[[@CR16]\]. In that study, the incidence of hepatoblastoma was analyzed according to sex and age. However, no outcomes were reported. In the present study, we have provided updated information on hepatoblastoma incidence trends. We found that its incidence increased by 2.2% annually from 2000 to 2015 and, notably, that the incidence increased most significantly among males and in 2- to 4-year-old children.

In the past decades, the management of hepatoblastoma has evolved to include not only surgical treatments such as liver resection and transplantation but also non-surgical treatments such as chemotherapy. Progress in treatment has contributed to prolonged OS in patients with hepatoblastoma. The 10-year OS rate was 81.0% in our analysis, which was better than 61% reported in a SEER-based analysis from 1973 to 2009 \[[@CR8]\]. In a single-center retrospective study involving 30 patients younger than 18 years who underwent liver transplantation for hepatoblastoma between 1997 and 2014 at Stanford University School of Medicine, Pham et al. \[[@CR11]\] reported 10-year disease-free survival and OS rates of 82% and 84%, respectively. In another SEER study including 318 hepatoblastoma patients undergoing surgery between 1998 and 2009, McAteer et al. \[[@CR27]\] found that the overall 5-year disease-specific survival rate was 85.7%, and the rates for patients undergoing resection and transplantation were essentially equivalent (85.6% vs. 86.5%, *P* = 0.66). In the present study, patients who underwent liver resection (*n* = 341) and liver transplantation (*n* = 84) had comparable 10-year OS rates (89.3% vs. 90.1%, *P* = 0.891).

Surgery, ethnicity, and age were identified as independent prognostic factors in the present study. Surgery was a strong predictor of OS. Moreover, the need for liver resection has increased over time: the number of patients receiving liver resection for hepatoblastoma increased by 1.4 folds between the time frames of 2004--2007 and 2012--2015. However, this increase was not observed in patients that received liver transplantation. The number of patients who underwent liver transplantation remained relatively constant between 2004--2007 and 2012--2015. These data emphasize that more children now have the opportunity for a possible cure by surgical resection. With advances in surgical management and chemotherapy, the 5-year OS rate for children with hepatoblastoma has increased to more than 80%. In the current study, we included patients diagnosed between 2004 and 2015 that had been reported in SEER. There is no doubt that these patients mainly benefited from efficient surgical management and the use of novel chemotherapy regimens in the modern era.

It has been reported that age of \< 5 years old was a favorable factor for survival \[[@CR8]\]. In the present analysis, the 0- to 1-year-old group had the longest OS, whereas the 2- to 4-year-old group had the shortest OS. African--Americans also had shorter OS compared with Caucasians and other ethnicities. This finding was consistent with previous studies \[[@CR14], [@CR28]\]. It can be speculated that patients of African--American ethnicity may have had less access to surgical care. Further investigation is necessary to determine if a variation in tumor biology or another etiology is driving this trend. Further surrogate measures, such as poverty/household income, geographic origin of the patient, proximity to surgical centers/tertiary hospitals, or perhaps similarities with the epidemiology of other types of embryonal cancers, can be analyzed in other longitudinal databases with a wider range of epidemiological data as well.

In the present study, distant disease at presentation was not found to be an independent factor for survival. This finding differed from the results of previous studies \[[@CR8], [@CR14]\], where it was shown to be a significant prognostic factor. The reason remains unclear, but this may be related to the increased use of chemotherapy, to which hepatoblastoma is highly sensitive \[[@CR11], [@CR29]\]. The fact that AFP was not an independent prognostic factor stands out when taking into account existing literature, but this can be attributed to the database effect and also the different use of AFP or the sporadic testing. Further longitudinal studies are needed to determine whether AFP can be used in predicting the prognosis of hepatoblastoma.

In the present study, we constructed a nomogram based on the results of multivariate analysis and included common clinical factors in the model. Our nomogram performed well in predicting OS, and its prediction was supported by the bootstrap-corrected C-index and calibration curve. However, this study contained some limitations. First, information on chemotherapy regimen used was not included, due to incomplete data and biases associated with unstated reasons for receiving or not receiving chemotherapy in the SEER database. Second, although our data were collected from 18 cancer registries of the SEER database, our sample size was still relatively small. The SEER program is a high-quality, population-based cancer registry. Case finding audits of high-volume facilities are routinely performed for data accuracy, completeness, and reporting timeliness. Each SEER registry is given an annual Data Quality Profile, which assesses the extent to which each registry provides data meeting contractual standards. Thus, the SEER registry robustly captures the first course of any cancer-directed surgery. However, given that chemotherapy is routinely used in clinical work, our results represent current treatment outcomes for hepatoblastoma. Third, we could only internally validate the nomogram \[[@CR30], [@CR31]\] because of the rarity of hepatoblastoma. Although the nomogram showed good discriminatory ability and the calibration curves were consistent, an external validation of the model is still necessary. Lastly, as a retrospective review, our study is inherently prone to selection bias.

Conclusions {#Sec12}
===========

Our study demonstrated incidence trends of hepatoblastoma in children younger than 18 years and constructed a nomogram to more accurately predict their long-term survival based on a population cohort. The nomogram showed a good predictive performance and may be a useful tool for estimating long-term OS and for better supporting patient counseling.
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